TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02910648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Go/No-Go Task
Description: Participants in the experimental group and control sham sound cues group will complete a computerized training task to facilitate learning to respond (press a computer key) to healthy food stimuli and to inhibit responses (not press a computer key) to unhealthy food stimuli. Participants in the control sham go/no-go group will complete a similar task with common office supplies (approach) and tools (inhibit). All participants will also complete a 24 hour dietary recall as described below.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Modified Go/No-Go Task
Description: Participants in the experimental group and control sham sound cues group will complete a computerized training task to facilitate learning to respond (press a computer key) to healthy food stimuli and to inhibit responses (not press a computer key) to unhealthy food stimuli. Participants in the control sham go/no-go group will complete a similar task with common office supplies (approach) and tools (inhibit). All participants will also complete a 24 hour dietary recall as described below.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Modified Go/No-Go Task
Description: Participants in the experimental group and control sham sound cues group will complete a computerized training task to facilitate learning to respond (press a computer key) to healthy food stimuli and to inhibit responses (not press a computer key) to unhealthy food stimuli. Participants in the control sham go/no-go group will complete a similar task with common office supplies (approach) and tools (inhibit). All participants will also complete a 24 hour dietary recall as described below.
Study: NCT01348867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured care led by a nurse consultant
Description: For the intervention group, patients will be followed up according to the following protocol. The structured care team consists of:~i) Diabetes Nurse Consultant to reinforce compliance; educate patients on insulin injection techniques and reinforce self-care including self blood glucose monitoring and lifestyle interventions, titration of medication.~ii) Technical Service Assistance to remind patients to take medications and/or give insulin injection, monitor blood glucose as prescribed, attend their next clinic appointment, encourage patients to report all side effects, self initiated change in regimen or concerns to diabetes nurse consultant and/or their doctors at the next follow up visit.
Study: NCT02367261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPI implant
Description: SPI implant - the original spiral implant
Study: NCT03036163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 - 40 mg
Description: 40 mg of PBTZ169 (1 capsule) orally once in fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 - 80 mg
Description: 80 mg of PBTZ169 (2 capsules 40 mg) orally once in fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 - 160 mg
Description: 160 mg of PBTZ169 (4 capsules 40 mg) orally once in fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 - 320 mg
Description: 320 mg of PBTZ169 (8 capsules 40 mg) orally once in fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 - 640 mg
Description: 640 mg of PBTZ169 (16 capsules 40 mg) orally once in fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 - 320 mg (multiple administration)
Description: 320 mg of PBTZ169 (8 capsules 40 mg) orally once per day in fasting state for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 - 640 mg (multiple administration)
Description: 640 mg of PBTZ169 (16 capsules 40 mg) orally once per day in fasting state for 14 days
Study: NCT02156713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CIMT Camp
Study: NCT00052468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TC
Study: NCT06011590

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention.
Study: NCT00740792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: fluticasone propionate 200 mcg one spray per nostril BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo one spray per nostril BID
Study: NCT04553029

Intervention type: OTHER
Intervention: No intervention
Description: This is a cross-sectional survey study evaluating prevalence, severity and associated factors in women with moderate-to-severe menopause-related vasomotor symptoms (MR-VMS).

Intervention type: OTHER
Intervention: No intervention
Description: This is a cross-sectional survey study evaluating prevalence, severity and associated factors in women with moderate-to-severe menopause-related vasomotor symptoms (MR-VMS).

Intervention type: OTHER
Intervention: No intervention
Description: This is a cross-sectional survey study evaluating prevalence, severity and associated factors in women with moderate-to-severe menopause-related vasomotor symptoms (MR-VMS).

Intervention type: OTHER
Intervention: No intervention
Description: This is a cross-sectional survey study evaluating prevalence, severity and associated factors in women with moderate-to-severe menopause-related vasomotor symptoms (MR-VMS).
Study: NCT03584698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 100Mcg Tab
Description: women will receive misoprostol 100 mcg (Misotac, Sigma Pharmaceuticals, Egypt) vaginally applied every 6 hours till cervical dilatation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 100Mcg Tab
Description: women will receive misoprostol 100 mcg (Misotac, Sigma Pharmaceuticals, Egypt) vaginally applied every 6 hours till cervical dilatation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evening Primrose Oil 1000 MG
Description: women will receive 4 capsules evening primrose oil 1000 mg (Primrose plus, Ema Pharm, Egypt) vaginally applied every 6 hours till cervical dilatation.
Study: NCT02313428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Topical Oxygen Chamber for Extremities
Description: Surrounds a limb and applies oxygen topically at a pressure slightly greater than atmospheric pressure to aid healing of chronic skin ulcers
Study: NCT01571505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV vaccination
Description: Randomized IPV or OPV to children aged at 39weeks.
Study: NCT04309006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTG and customized healing abutment
Description: screw- retained customized healing abutment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTG and customized healing abutment
Description: screw- retained customized healing abutment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTG and conventional healing abutment
Description: conventional healing abutment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTG and conventional healing abutment
Description: conventional healing abutment
Study: NCT04410003

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbial transplant
Description: Fecal microbial transplant

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fecal microbial transplant
Description: Fecal microbial transplant
Study: NCT01571505

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IPV vaccination
Description: Randomized IPV or OPV to children aged at 39weeks.
Study: NCT00564122

Intervention type: DEVICE
Intervention: Artificially-Intelligent Stethoscope
Description: After subjects' medical visits are complete, the heart sounds of all subjects will be recorded and assessed by an artificially-intelligent stethoscope. Attempts will be made to make satisfactory 20-second recordings from a total of eight positions on the chest with the patient in supine and upright positions.

Intervention type: OTHER
Intervention: Physical Examination
Description: A Pediatric Cardiologist will examine each subject to the extent needed to make clinical assessments. This represents the ordinary standard-of-care.
Study: NCT02477618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAGE-547

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03961165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylscopolamine Bromide 20 MG/ML
Description: 1 mL Butylscopolamine Bromide 20 mg/mL i.v. Single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/mL
Description: 1 mL Sodium Chloride 9 mg/mL i.v. Single dose.
Study: NCT04450108

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vivatmo pro FeNO Test
Description: Breath gas analysis
Study: NCT03375944

Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation
Description: The purpose of this work package is to evaluate short- and long-term clinical effects of optimal, continuous and regularly controlled tele-rehabilitation, which is based on exercise training, intensive dietary and educational program focused on lifestyle and risk factors modification. The main expectations of OCR is to normalize annual mortality to the level of the low risk healthy population.
Study: NCT03311438

Intervention type: OTHER
Group type: OTHER
Intervention: Oral health intervention program
Description: Intervention: All parents were encouraged to brush their children's teeth twice a day, with adjusted amount of fluoride toothpaste according to age. Additional fluoride tablets with dose according to age were recommended from two years of age. The children's parents were given written information about the importance and benefits of optimal oral hygiene and explaining the link to infective endocarditis. A pamphlet, lift the lip program, with instruction of looking for early signs of tooth decay, how to intervene and contact local Public Dental Service (PDS) clinic. Dietary advice was also given. The child's responsible dentist or dental hygienist at the local PDS was contacted with information about the project and the findings from examination.
Study: NCT01181206

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Arm 1: Covering with approved abdominal 3M™ Steri-Drape™ Wound Edge Protector Intervention Arm 2: Covering with standard woven swabs
Study: NCT03408717

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires including Pain catastrophizing scale (PCS), Central Sensitisation Inventory (CSI), Coping Strategies Questionnaire-Revised (CSQ-R), Brief Symptom Inventory-18 (BSI-18), Perceived Stress Scale (PSS), EQ-5D-3L and Eysenck Personality Questionnaire (EPQ) will be administered to the patient.

Intervention type: OTHER
Intervention: Mechanical Temporal Summation assessment
Description: A 180 gram von Frey filament is applied on the subject's forearm. Patient will then be asked to rate the pinprick pain score on a verbal rating scale, 0-100. Following this, 10 consecutive touches at random locations are applied with a 1 second interstimulus interval and within a 1 cm diameter circle. The patient will then be asked to rate the 10th pain score (0-100). The Mechanical Temporal Summation Score is obtained by the difference between the 11th pain score and the 1st pain score. If the score is greater than zero, the patient is implied to have presence of Mechanical Temporal Summation.

Intervention type: OTHER
Intervention: Pain threshold assessment
Description: Pressure is applied 90 degree straight down force on the subject's right/left centre of the trapezius muscle using an algometer, with a speed of pressure \~ 1kgf/s. The above procedure is then repeated 3 times at each site (left/right) which is indicated on the pressure mark with each time having the reading recorded. When patient shows no response ≥ 6kgf, the threshold is recorded as 6kgf. The patient upon feeling pain will say stop or raise the hand to terminate the test. The mean value is obtained by averaging the readings and will then be recorded as the threshold estimate.
Study: NCT02127645

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SRT-TEM
Description: SRT-TEM underwent 25 Gy RT followed by TEM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LRT-TEM
Description: TEM following 46 Gy RT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal Endoscopic Microsurgery (TEM)
Description: Transanal Endoscopic Microsurgery (TEM)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Mesorectal Excision (TME)
Description: Laparoscopic Total Mesorectal Excision
Study: NCT03915535

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic acid + Docosahexaenoic acid
Description: Monoglyceride Omega-3 fish oils

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid
Description: Monoglyceride Omega-3 fish oil
Study: NCT02494076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EzPAP

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Care
Study: NCT01945593

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX855
Description: Antihemophilic Factor (Recombinant), PEGylated

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX855
Description: Antihemophilic Factor (Recombinant), PEGylated
Study: NCT03533803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin 100Mg Suppository
Description: Indomethacin 100Mg Suppository will be given 1 to 2 hours before embryo transfer in cases with difficult mock embryo transfer in the active comparator group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI
Description: patients received induction with the long agonist stimulation protocol. Followed by ovum pickup and embryo transfer. Only those with difficult mock embryo transfer will be recruited in this study.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: IVF/ICSI
Description: patients received induction with the long agonist stimulation protocol. Followed by ovum pickup and embryo transfer. Only those with difficult mock embryo transfer will be recruited in this study.
Study: NCT02001649

Intervention type: GENETIC
Group type: OTHER
Intervention: SNP Genotyping
Description: Individuals were genotyped at a total 96 SNP from 15 candidate gene

Intervention type: GENETIC
Group type: OTHER
Intervention: SNP genotyping
Study: NCT03520088

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior mesenteric Vein dissection
Description: Dissection of the Inferior mesenteric Vein first, and go down to the Artery during the total mesorectal excision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior mesenteric Artery dissection
Description: Dissection of the Inferior mesenteric Artery directly in the total mesorectal excision
Study: NCT01291043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shiatsu
Description: 8-week treatment with two Shiatsu sessions per week (50-minute duration)
Study: NCT03469258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Description: Zenpep is a combination of three enzymes (proteins). These enzymes are normally produced by the pancreas and are important in the digestion of fats, proteins, and sugars. Zenpep is used to replace these enzymes when the body does not have enough of its own as a result of surgery and/or pancreatic cancer.
Study: NCT03865940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 6 mL of 1% lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 6 mL of 1% lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: 250 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: 250 mcg
Study: NCT00627523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genotropin (PN-180,307) Somatropin
Description: Injectable Genotropin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control-no treatment
Description: Control-no treatment
Study: NCT02367664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5ml experimental vaccine on day 0,7 Vero cell-derived inactivated Japanese Encephalitis vaccine
Description: Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5ml experimental vaccine on day 0,28 Vero cell-derived inactivated Japanese Encephalitis vaccine
Description: Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 28 days interval, a booster dose 12 months after the first dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0.5ml active comparator vaccine on day 0,7 inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell)
Description: inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell) produced by Beijing Tiantan Biological Products Co., Ltd. /0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
Study: NCT03889912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Each patient will receive intralesional injections of cemiplimab every week (QW), or at less frequent dosing into the lesion at the assigned dose level for 3-12 weeks prior to scheduled surgery
Study: NCT03409276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: env (A,B,C,A/E)/gag (C) DNA Vaccine
Description: Administered by intramuscular injection in the deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: env (A,B,C,A/E)/gag (C) DNA Vaccine
Description: Administered by intramuscular injection in the deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp120 (A,B,C,A/E) Protein Vaccine
Description: Administered by intramuscular injection in the deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp120 (A,B,C,A/E) Protein Vaccine
Description: Administered by intramuscular injection in the deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp120 (A,B,C,A/E) Protein Vaccine
Description: Administered by intramuscular injection in the deltoid.
Study: NCT01290835

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy delivered by CyberKnife
Description: Adjuvant radiotherapy will be delivered using CyberKnife radiotherapy using twice daily sessions for five days for a total of ten sessions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiotherapy
Study: NCT06751875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Patients are randomized to either receive lithium or not.
Study: NCT01602536

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation aides
Description: All participants will receive 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation aides
Description: All participants will receive 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Twitter
Description: Twitter quit-smoking group
Study: NCT00755989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine topical gel
Description: morphine gel 0.1%, applied every 12 hours to stage 2-3 wound, during their hospital stay

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: topical gel without morphine
Study: NCT02265042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulette
Description: electrical stimulation device by Dr. Schuhfried Medizintechnik GmbH, Vienna, Austria
Study: NCT03409276

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE adjuvant
Description: Administered by intramuscular injection in the deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE adjuvant
Description: Administered by intramuscular injection in the deltoid.
Study: NCT00244504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxonidine
Description: moxonidine 0.2 mg/d starting the morning of surgery until day 4 after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: moxonidine
Description: moxonidine 0.2 mg/d starting the morning of surgery until day 4 after surgery
Study: NCT03823118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1/Anlotinib
Description: Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
Study: NCT04020991

Intervention type: DIAGNOSTIC_TEST
Intervention: Sleep Study
Description: Participants who noted to have Oxygen Desaturation Index more than 10 (moderate to severe OSA) will be referred to do formal sleep study and referral to Sleep Medicine Clinic
Study: NCT01108848

Intervention type: BIOLOGICAL
Intervention: Berinert® (C1 Esterase Inhibitor)
Description: Berinert® is marketed as a lyophilized concentrate available in a single-use vial to be reconstituted with sterile water before administration as described in the prescribing information.
Study: NCT04575896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir
Description: Glecaprevir/pibrentasvir 300mg/120mg once daily by mouth for 2 weeks post-transplant.
Study: NCT04537923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro (U100)
Description: Administered SC